Axogen prices $124M public offering at $31/share; proceeds to pay off $69.7M credit facility

Axogen, Inc.

Pricing of upsized 4M share offering at $31.00/share for gross proceeds of ~$124M (assuming no over-allotment).
Net proceeds used primarily to repay ~$69.7M term loan with Oberland Capital, terminating that credit facility.
Underwriters granted 30-day option to purchase up to an additional 600K shares (~$18.6M).
Offering expected to close on January 23, 2026; Wells Fargo and Mizuho are lead book-running managers.
Remaining net proceeds for working capital, capital expenditures, and general corporate purposes.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

Axogen, Inc. entered into Underwriting Agreement with Wells Fargo Securities, LLC and Mizuho Securities USA LLC, as representatives of the underwriters valued at 4,000,000 shares of its common stock, $0.01 par value per share, at a public offering price of $31.0 (effective 2026-01-21).

Action: entry
Agreement: underwriting
Counterparty: Wells Fargo Securities, LLC and Mizuho Securities USA LLC, as representatives of the underwriters
Value: 4,000,000 shares of its common stock, $0.01 par value per share, at a public offering price of $31.0
Effective: 2026-01-21

Exact text from the filing

On January 21, 2026, Axogen, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Wells Fargo Securities, LLC and Mizuho Securities USA LLC, as representatives of the underwriters (the “Underwriters”).

View on SEC.gov

336 material agreements filed in the last 30 days. Browse all material agreements →

Axogen, Inc. filing history →

Source: SEC EDGAR

accession 0000805928-26-000026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.